Benitec Biopharma (BNTC) FCF Margin (2019 - 2023)

Benitec Biopharma (BNTC) posted FCF Margin of 58342.86% for Q2 2023, down 684.3% sequentially from 7438.89% in Q1 2023.

Benitec Biopharma (BNTC) FCF Margin (2019 - 2023) Analysis & Trends

Benitec Biopharma has reported FCF Margin for 5 years, with the latest figure at 58342.86% in Q2 2023.

Quarterly FCF Margin changed N/A year-over-year to 58342.86% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 288485.71% (down 26079454.0% YoY) and the FY2023 annual result came in at 24001.33%, down 220270.0% from the prior year.
FCF Margin eased to 58342.86% in Q2 2023 per BNTC's latest filing, from 7438.89% in the prior quarter.
Over five years, FCF Margin peaked at 9022.86% in Q2 2020 and troughed at 346000.0% in Q4 2020.
A 5-year average of 71471.89% and a median of 7438.89% in 2023 frame the typical range for FCF Margin.
The sharpest annual moves came in 2020 and 2021: FCF Margin plunged 34200519 bps in 2020, then soared 33280000 bps in 2021.
Over 5 years, FCF Margin stood at 3994.81% in 2019, then sank by 8561 bps to 346000.0% in 2020, then surged by 96 bps to 13200.0% in 2021, then sank by 217 bps to 41821.43% in 2022, then plunged by 40 bps to 58342.86% in 2023.
According to Business Quant data, FCF Margin over the past three periods registered 58342.86%, 7438.89%, and 41821.43% for Q2 2023, Q1 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Benitec Biopharma	577.39 Mn	388.49 Mn	-	-

Download Data